Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 3 Clinical effects in this phase I study

From: BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study

Patient no. HB-EGF in serum (pg/mL) HB-EGF in abdominal fluid (pg/mL) Serum CA125 (IU/mL) Anti-diphtheria toxin antibodies (IU/mL) Efficacy
Pre-Tx Post-Tx Pre-Tx Post-Tx Pre-Tx Post-Tx Pre-Tx Post-Tx
1 1971 196 2169 106 291 137 <0.01 2.56 SD
2 556 349a 416 560a 1411 3487 <0.01 124 PD
3 297 172 593 292 46 50 <0.01 >131 SD
4 267 85 143 34 1408 2217 0.04 >131 PR
5 51 101 55 399 267 600 0.03 31.1 SD
6 74 109 109 171 254 158 <0.01 81.9 PD
7 67 79 130 ND 2813 3983 <0.01 0.06 PD
8 162 141a 140 132a 3894 5147 0.13 20.5 PD
9 231 130 237 66 1856 3984 0.01 1.02 PD
10 247 140 ND ND 40 63 <0.01 >41.0 SD
11 67 155a ND ND 16 94 <0.01 >6.56 SD
  1. Pre-A pre-administration of BK-UM, Post-A post-administration of BK-UM, ND not determined, SD stable disease, PD progressive disease, PR partial response
  2. aHB-EGF level was measured on the final day of investigation